PrepQuant system launched

Molecular tests start with a basic step: turning blood or bone marrow into usable genetic material. Invivoscribe said Wednesday its new PrepQuant system automates that front end in one instrument. (invivoscribe.com) The San Diego company said the platform combines nucleic acid extraction, concentration, and quantification, which are usually separate sample-prep steps before next-generation sequencing, quantitative polymerase chain reaction, or digital polymerase chain reaction testing. Invivoscribe announced the launch on April 15, 2026. (businesswire.com) In plain terms, labs first have to pull DNA or RNA out of a patient sample, measure how much they recovered, and make sure it is concentrated enough to run a molecular test. Invivoscribe said PrepQuant is meant to handle those steps on a single automated platform and is assay agnostic, meaning it is designed to feed multiple downstream test types rather than one proprietary assay. (invivoscribe.com) That matters in cancer diagnostics because small differences in handling a sample before the actual test can change the quality of the result. Invivoscribe’s business centers on precision diagnostics and measurable residual disease testing, which looks for tiny numbers of cancer cells left after treatment. (invivoscribe.com) Invivoscribe said the system was developed with Hitachi High-Tech, which makes clinical and life-science instruments and took a minority stake in Invivoscribe in 2021 as part of a molecular diagnostics partnership. The two companies said at the time they planned to combine Invivoscribe’s assay and testing expertise with Hitachi High-Tech’s instrument and manufacturing capabilities. (invivoscribe.com) The first validated specimen types are blood, plasma, and bone marrow, according to the company. Invivoscribe said additional specimen types are in development and that new kit releases are expected by the end of 2026. (invivoscribe.com) The company plans to show the instrument publicly at the American Association for Cancer Research annual meeting in San Diego from April 17 through April 22, where it said it will exhibit at booth 3459. The conference organizer lists the 2026 meeting in San Diego on those dates. (invivoscribe.com) (aacr.org) Invivoscribe has sold leukemia and lymphoma testing products for more than 30 years, and PrepQuant extends that business into the sample-preparation step that happens before analysis. The pitch is straightforward: fewer manual handoffs, less bench space, and more consistent input for molecular tests. (invivoscribe.com)